CLSDQClearside Biomedical, Inc.

About Clearside Biomedical, Inc. (CLSDQ)

Clearside Biomedical, Inc. (CLSDQ) is a company headquartered in Alpharetta, GA, United States whose shares trade over-the-counter on the Pink tier.

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc.

CLSDQ key facts

Ticker symbol

CLSDQ

Market tier

Pink

Headquarters

Alpharetta, GA, United States

Country of incorporation

US

Estimated market cap

$4.40M (as of Jan 12, 2026)

Shares outstanding

5,233,981

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Dec 19, 2025)

Explore more: Pink stocks · OTC stocks starting with C